Showing 5081-5090 of 8223 results for "".
- Scientific First: Researchers Grow Hairy Skin In A Dishhttps://practicaldermatology.com/news/scientific-first-researchers-grow-hairy-skin-in-a-dish/2457934/Indiana University School of Medicine researchers have successfully developed a method to grow hairy skin from mouse pluripotent stem cells—a discovery that could lead to new approaches to model disease and new therapies for the treatment of skin disorders and cancers. This res
- DermTech Receives Health Canada Approval to Market PLA and Non-invasive Biopsy Kithttps://practicaldermatology.com/news/dermtech-receives-health-canada-approval-to-market-pla-and-non-invasive-biopsy-kit/2457937/DermTech, Inc's licensee, DermTech Canada Inc., has received approval to market DermTech’s Pigmented Lesions Assay (PLA) and non-invasive biopsy kit for the detection of melanoma in Canada. DermTech Canada will market and sell the PLA, and samples will be processed at DermTech’s c
- Daily Facial Exercises Help Women to Look Three Years Younger in 20 Weekshttps://practicaldermatology.com/news/daily-facial-exercises-help-women-to-look-three-years-younger-in-20-weeks/2457938/A 30-minute daily or alternate-day facial exercise program sustained over 20 weeks improved the facial appearance of middle-aged women, resulting in a younger appearance with fuller upper and lower cheeks, reports a new Northwestern Medicine study. This is the first scientific study to te
- FDA Approves BMS's Opdivo as Adjuvant Therapy in Patients with Completely Resected Melanoma with Lymph Node Involvement or Metastatic Diseasehttps://practicaldermatology.com/news/fda-approves-bmss-opdivo-as-adjuvant-therapy-in-patients-with-completely-resected-melanoma-with-lymph-node-involvement-or-metastatic-disease/2457941/The FDA has approved Bristol-Myers Squibb Company's Opdivo (nivolumab) injection for intravenous use for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection. The purpose of adjuvant therapy is to reduce t
- FDA Accepts NDA for Allergan, Paratek Acne Drughttps://practicaldermatology.com/news/fda-accepts-nda-for-allergan-paratek-acne-drug/2457946/The U.S. Food and Drug Administration accepted a New Drug Application (NDA) to review SeysaraTM(sarecycline) for the treatment of moderate to severe acne vulgaris in patients 9 years of age and older, Allergan plc and Parate
- Study: Minorities Less Likely to See a Doctor for Psoriasishttps://practicaldermatology.com/news/study-minorities-less-likely-to-see-a-doctor-for-psoriasis/2457954/Minorities are less likely than white Americans to see a doctor for psoriasis treatment despite the fact that their disease may be more severe, a new study shows. Researchers from the Perelman School of Medicine at the University of Pennsylvania fou
- Allergan's CoolSculpting Treatment Now FDA Approved to Improve Appearance Of Lax Tissue in Double Chinhttps://practicaldermatology.com/news/allergans-coolsculpting-treatment-now-fda-approved-to-improve-appearance-of-lax-tissue-in-double-chin/2457956/The FDA has approved Allergan plc's CoolSculpting treatment for improved appearance of lax tissue in conjunction with submental fat, or double chin, treatments. CoolSculpting for the double chin is already clinically proven to reduce fat up to 20 percent in the treated area after one tr
- Revance: RT002 Achieves 6-Month Duration in Phase 3https://practicaldermatology.com/news/revance-rt002-achieves-6-month-duration-in-phase-3/2457959/Revance Therapeutics’ next-generation neuromodulator DaxibotulinumtoxinA for Injection (RT002) delivered positive top-line results in alleviating moderate-to-severe glabellar lines in two pivotal SAKURA Phase 3 trials with duraction of effect up to 6 months. RT002 appeared ge
- FDA Grants Extended Clearance of the Describe Patch for Tattoo Removalhttps://practicaldermatology.com/news/fda-grants-extended-clearance-of-the-describe-patch-for-tattoo-removal/2457960/Merz North America’s DESCRIBE® PFD Patch is now cleared by the Food and Drug Administration (FDA) for all commonly used lasers for tattoo removal. The new FDA clearance also extends the shelf life of the Patch from two years
- AI in Action: New Machine Learning Technique May Enhance Computer-aided Diagnosis of Melanomahttps://practicaldermatology.com/news/ai-in-action-new-machine-learning-technique-may-enhance-computer-aided-diagnosis-of-melanoma/2457963/Researchers at Florida Atlantic University’s College of Engineering and Computer Science have developed a technique using machine learning – a sub-field of artificial intelligence (AI) – that will enha